Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in graves' disease: A retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission

Endocrine Journal

Volumn 58, Issue 2, 2011, Pages 95-100

  Konishi, Toshiaki ^a   Okamoto, Yasuyuki ^b   Ueda, Miki ^a   Fukuda, Yoshiko ^a   Harusato, Ichiko ^b   Tsukamoto, Yuka ^a   Hamada, Noboru ^a  

^a Sumire Hospital   (Japan)

^b Sumire Clinic   (Japan)

Author keywords

Antithyroid drug treatment; Drug discontinuation; Graves' disease; Remission rate; TSH receptor antibody

Indexed keywords

ANTITHYROID AGENT; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GRAVES DISEASE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REMISSION; THYROXINE BLOOD LEVEL; TREATMENT DURATION;

ADOLESCENT; AGED; ANTITHYROID AGENTS; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; JAPAN; MALE; METHIMAZOLE; MIDDLE AGED; PROPYLTHIOURACIL; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; THYROID GLAND; THYROTROPIN; THYROXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952724567     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-262     Document Type: Article

References (30)

1. Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD (1989) Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Scottish Automated Follow-Up Register Group. Clin Endocrinol (Oxf). 31: 209-218.
2. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR et al (1989) Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 120: 689-701.
3. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7: 369-375.
4. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF (1995) Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 273: 808-812.
5. Vanderpump MP, Ahlquist JA, Franklyn JA, Clayton RN (1996) Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology.BMJ 313: 539-544.
6. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL; American Association of Clinical Endocrinologists. (2002) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 8: 457-469.
7. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, Lescouarch J, Herry JY, Allannic H (1999) Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 50: 127-132.
8. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. (1991) Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1: 129-135.
9. Glinoer D, Hesch D, Lagasse R, Laurberg P (1987) The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol (Copenh) 285 (Suppl): 3-23.
10. Yamamoto M, Totsuka Y, Kojima I, Yamashita N, Togawa K, Sawaki N, Ogata E (1983) Outcome of patients with Graves' disease after long-term medical treatment guided by triiodothyronine (T3) suppression test. Clin Endocrinol (Oxf) 19: 467-476.
11. Takasu N, Akamine H, Komiya I, Yamada T (1995) Simple and reliable method for predicting the remission of Graves' disease: revised triiodothyronine-suppression test, indexed by serum thyroxine. J Endocrinol Invest. 18: 288-294.
12. Dahlberg PA, Karlsson FA, Jansson R, Wide L (1985) Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission. J Clin Endocrinol Metab 61: 1100-1104.
13. Notsu K, Oka N, Masaki Y, Furuya H, Kato Y (1991) Plasma tree triiodothyronine response to thyrotropin-releasing hormone to predict the remission of Graves' disease treated with antithyroid drugs. J Clin Endocrinol Metab 73: 396-400.
14. Takamatsu J, Kuma K, Mozai T (1986) Serum triiodothyronine to thyroxine ratio: A newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease. J Clin Endocrinol Metab 62: 980-983.
15. Kawamura S, Kishino B, Tajima K, Mashita K, Tarui S (1983) Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy. J Clin Endocrinol Metab 56: 507-512.
16. Talbot JN, Duron F, Feron R, Aubert P, Milhaud G (1989) Thyroglobulin, thyrotropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves' disease within one year. J Endocrinol Invest 12: 589-595
17. Chowdhury TA, Dyer PH (1998) Clinical, biochemical and immunological characteristics of relapsers and non-relapsers of thyrotoxicosis treated with anti-thyroid drugs. J Intern Med 244: 293-297.
18. Winsa B, Dahlberg A, Jansson R, Agren H, Karlsson FA (1990) Factors inluencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol (Copenh) 122: 722-728.
19. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P (1998) The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 8: 119-124.
20. Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A (2000) Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid 10: 891-896.
21. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, Seissler J (2004) Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm Metab Res 36: 92-96.
22. Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Rosei EA (2007) Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study. Endocr J 54: 713-720.
23. Feldt-Rasmussen U, Schleusener H, Carayon P (1994) Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 78: 98-102.
24. Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, Kuma K (1995) A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Clin Endocrinol (Oxf) 43: 551-556.
25. Guideline for the treatment of Graves' disease with antithyrid drug in Japan. The Japan Thyroid Association, 2006, Nankodo Co., Ltd., Tokyo.
26. Tajiri J, Noguchi S, Morita M, Tamaru M, Murakami N (1991) Antithyroid drug therapy for Graves' hyperthyroidism: is long-term administration of a small maintenance dose necessary? Endocrinol Jpn 38: 223-227.
27. Okamoto Y, Tanigawa S, Ishikawa K, Hamada N (2006) TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 53: 467-472.
28. Kashiwai T, Hidaka Y, Takano T, Tatsumi KI, Izumi Y, Shimaoka Y, Tada H, Takeoka K, Amino N (2003) Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Endocr J 50: 45-49.
29. Mashio Y, Beniko M, Matsuda A, Koizumi S, Matsuya K, Mizumoto H, Ikota A, Kunita H (1997) Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. Endocr J 44: 553-558.
30. Laurberg P (2006) Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 155: 783-786.